Phase 3 Trial Launched to Test TTFields-Taxol Combo on Platinum-resistant Ovarian Cancer

Phase 3 Trial Launched to Test TTFields-Taxol Combo on Platinum-resistant Ovarian Cancer
Novocure has initiated a Phase 3 trial investigating its Tumor Treating Fields (TTFields) — a method that uses electric fields to disrupt cell division — in combination with Taxol (paclitaxel) as a treatment for ovarian cancer patients who are resistant to platinum-based chemotherapy. The trial — which is for women who received up to two prior lines of therapy after developing resistance to platinum-based chemotherapy — comes after promising findings from the INNOVATE Phase 2 trial (NCT02244502), where the combination more than doubled the time patients lived without disease worsening, compared with historical controls treated with Taxol alone. Ovarian cancer, a disease that affects 22,500 women every year in the U.S., is often treated with a chemotherapy regimen containing a platinum agent, such as cisplatin or carboplatin. However, while most patients respond, the majority will see their cancer return or progress within a few months. These patients — platinum-resistant ovarian cancer patients — have numerous therapies available, but survival rates are low. “Ovarian cancer is one of the most aggressive forms of cancer,” Ignace Vergote, chairman of the department of obstetrics and gynaecology and gynaecologic oncology at the Catholic University of Leuven, in Belgium, said in a press release. “Most ovarian cancer patients are diagnosed at an advanced stage, which makes the disease difficult to treat. Current treatment options are not enough for these patients. We are pleased to begin this trial that has the potential to improve survival in recurrent ovarian cancer,” he added. Taxol is another chemotherapy agent that leads to high response rates in platinum-resistant patients, and studies in the lab have shown that TTFields works in s
Subscribe or to access all post and page content.